Artrya Limited · ASX:AYA
Artrya — Euroz Hartleys Healthcare Forum 2023
15 slides from Artrya's conference presentation, Feb 2, 2023
Slide 1: Euroz Hartleys Healthcare Forum 2023
For personal use only Euroz Hartleys Healthcare Forum 2023 February 2023
Slide 2: Important notice and disclaimer
Important notice and disclaimer of this presentation, nor has it verified any of the contents of this presentation. You must consider your own financial situation, objectives and needs and conduct your own IMPORTANT NOTICE independent investigations, assessments and enquiries, including obtaining in
Slide 3: Global Problem: Coronary Artery Disease is a leading cause of death globally
Global Problem Coronary Artery Disease is a leading cause of death globally For personal use only 126 $400 Every 13 One Nine million billion minutes third million people with heart disease costs Someone in of deaths globally CAD deaths significant the United States Australia dies of a are from heart
Slide 4: The culprit: Vulnerable Plaque
The culprit: Vulnerable Plaque Unstable soft plaque that ruptures For personal use only 4% plaque burden = 5x increased risk of heart attack1 BUILD UP OF PLAQUE VULNERABLE PLAQUE IS DIFFICULT TO SEE AND RARELY REPORTED. 4 © ARTRYA Private & Confidential © ARTRYA 1. Williams, M.C. et al. (2020) “Low-
Slide 5: Artrya Salix reports Vulnerable Plaque within minutes
Artrya Salix reports Vulnerable Plaque within minutes For personal use only 5 © ARTRYA Private & Confidential
Slide 6: Salix cuts overall scan-to-report time, reducing cost with high accuracy
Salix cuts overall scan-to-report time, reducing cost & with high accuracy at the point-of-care Salix Coronary Anatomy (SCA) For personal use only <15 minutes Radiologist / Manual Image Radiographer Referring Patient CCTA Scan Cardiologist clinician Post-Processing Workup Assess and report Current W
Slide 7: Salix delivers benefits to clinicians and patients from a single point-of-care solution
Salix delivers benefits to clinicians and patients from a single point-of-care solution For personal use only Radiographer Radiologist Cardiologist Patient Imaging Workflow Patient Improved Automation Optimisation Insight Outcomes • Artery tracking • Within 15 minutes • Rapid assessment • Faster dia
Slide 8: The product and its development
The product and its development For personal use only Artrya’s product pipeline goes further & moves us towards predicting the patient at risk. WHOLE HEART SEVERITY OPTIMISED VULNERABLE CHARACTERISATION PROCEDURE PATIENT Blood flow FOR CAD assessment Vulnerable Patient Procedure & Vulnerable Plaque
Slide 9: Global market 20m CCTA scans growing 5% p.a.
Global market 20m CCTA scans growing 5% p.a. For personal use only Europe North 17% America 25% 8 7 CT volumes (m) 7.1 6 14% Rest of 5 COVID-19 4.2 4.4 World impact 19% APAC 4 39% 3 2.4 2.5 2.5 2 1.8 2.7 1 1.6 1.7 1.7 1.2 0 CY18 CY19 CY20 CY21 CY25 Europe North America Source: Frost & Sullivan USA U
Slide 10: Product refinement & regulatory approval
Product refinement & regulatory approval STATUS For personal use only PILOT STUDIES REGULATORY APPROVALS Learnings from Australian pilot studies Australia 400 scans a month New Zealand through Salix European CE Mark Stability UK Conformity Assessment Performance FDA strategy implementation Ongoing A
Slide 11: Revenue generation
Revenue generation For personal use only SaaS business model… GLOBAL AVAILABILITY Freemium Pay-Go Charge a single flat fee 24/7 Market entry Access a free version Scalability per image scanned. for a limited period HIGH GROSS MARGIN Value- Significant uplift in Subscription Annuity stream for based
Slide 12: Our people – Artrya Ltd Board of Directors
Our people – Artrya Ltd Board of Directors For personal use only Chair Co-Founder & Co-Founder & Non-Executive Director Bernie Ridgeway Managing Director Executive Director Dr Jacque Sokolov John Barrington AM John Konstantopoulos 12 © ARTRYA Private & Confidential
Slide 13: Our people – Clinical Advisory Board
Our people – Clinical Advisory Board For personal use only Jacque Sokolov, MD Jacob Agris MD, PhD Jack Lewin, MD Professor Girish Dwivedi, MD Michael Ridner, MD Thomas Cheek, MD James C. Bonnette, MD Nicolas Chronos, MD Professor Benjamin Chow, MD 13 © ARTRYA Private & Confidential
Slide 14: Artrya – Financial & Trading Information
Artrya – Financial & Trading Information For personal use only • Quarterly cash outflows $3.6m (previous quarter $5.1m) ASX: AYA Trading Chart • Average monthly net cash burn $1.2m (previous quarter $1.7m) • Operational efficiencies $0.5m cash saving per mth since mid-2022 ASX: AYA Trading Informati
Slide 15: Summary
Summary For personal use only • Australian pilot site learnings incorporated into product • First Australian contracts expected FY23 • United Kingdom UKCA regulatory approval • 4-year contract with UK National Health Service • European CE Mark regulatory approval • FDA strategy being implemented • U